Tekaje

What Tekaje does

Tekaje is a privately owned Iranian pharmaceutical company founded in 1997 and headquartered in Tehran, operating a fully integrated value chain from regulatory affairs and formulation R&D through manufacturing, distribution, sales, and pharmacovigilance. The company develops, manufactures, and sells pharmaceutical and consumer healthcare products, generating revenue through one-time product sales of tablets, film tablets, capsules, pellets, sachets, and dietary supplements sourced either from international partners, through co-development, or via in-house R&D. Its commercial portfolio spans more than 150 molecules and dietary supplements, with a branded set including Exerect, Bicalox, Staparkin, Matever, Hye, Xiloial, Pure, and EyeGel promoted across urology, neurology, and ophthalmology congresses.

The technical backbone consists of a cGMP-compliant production facility in Eshtehard, Alborz province — a 5,000 m2 plant representing a $10 million capital investment with 350 million units annual capacity on two shifts, certified to GMP, ISO 9001, and ISO 14001 standards. R&D operates since 2007 from the Iran Polymer and Petrochemical Institute via three specialized units (formulation, analysis, documentation) equipped with rotary presses, tablet coating systems, HPLC, UV spectrophotometers, dissolution apparatus, and accelerated stability chambers, with a pipeline of 40+ molecules and CTD documentation capability aligned to FDA-style registration.

The go-to-market is an enterprise field sales motion: medical representatives detail 110,000 Iranian healthcare practitioners, line supervisors and senior medical advisors manage key accounts with KOLs and medical associations, market access managers deliver pharmacoeconomic studies to insurance companies covering roughly 90% of the population, and commercial sales managers run pharmacy, hospital, and wholesaler relationships. Distribution reaches approximately all 10,000 pharmacies and 11,000 hospitals in Iran through GDP-validated warehousing and delivery infrastructure, with secondary international presence in selected other countries and a consumer-facing Tekaje LIFE platform offering 24/7 patient consultations and health awareness content.

Name

Tekaje

Legal name

Tekaje

Website

https://tadbirkala.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

51–100 employees

Short description

Tekaje is a privately owned Iranian pharmaceutical company founded in 1997 that develops, manufactures, and distributes a 150+ molecule portfolio of generic and branded pharmaceuticals plus dietary supplements, reaching all 10,000 pharmacies and 11,000 hospitals in Iran through a cGMP-certified facility.

Ownership category

akta.pro rank

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Tekaje generates business through products that are either acquired from partners, co-developed with partners, or individually developed by their R&D team. Products include tablets, film tablets, capsules, pellets, sachets, and dietary supplements distributed through wholesalers to pharmacies and hospitals.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Tekaje is a fully integrated pharmaceutical company that develops, manufactures, and distributes pharmaceutical products and dietary supplements. The company produces solid oral dosage forms (tablets, film tablets, capsules, pellets, sachets) and offers a portfolio of more than 150 molecules and dietary supplements, with 40+ molecules in its R&D pipeline. Products are distributed through wholesalers to approximately 10,000 pharmacies and 11,000 hospitals across Iran, with the company operating its own GMP-certified manufacturing facility, R&D laboratories, and nationwide distribution network.

Product overview

Tekaje is a fully integrated pharmaceutical company offering a portfolio of more than 150 molecules and dietary supplements. The company manufactures solid dosage forms including Tablets, Film Tablets, Capsules, Pellets, and Sachets at its GMP-certified facility in Eshtehard, Iran. Specific branded pharmaceutical products include Exerect and Bicalox (urology), Staparkin and Matever (neurology/CNS), and Hye, Xiloial, Pure, and EyeGel (ophthalmology). Tekaje serves patients through distribution to approximately 10,000 pharmacies and 11,000 hospitals across Iran, with regulatory affairs coordination through Iran's Food & Drug Administration (IFDA).

Differentiator

Problem solved

Functional benefit

Brands

• Tekaje LIFE: A platform focusing on defining shared values to empower local communities and underserved patients to promote healthier life, including affordable products, health awareness via social marketing, and personalized health awareness via measuring specific health condition indexes and medical consultation line.

Products and services

• Pharmaceutical Manufacturing (Tablets, Film Tablets, Capsules, Pellets, Sachets) Solid oral pharmaceutical dosage forms (tablets, film tablets/pills, capsules, pellets, sachets) manufactured in Tekaje's cGMP-compliant Eshtehard facility for distribution to pharmacies and hospitals across Iran. These products serve patients in various therapeutic areas and are part of Tekaje's portfolio of more than 150 molecules.
• Dietary Supplements Consumer healthcare dietary supplement products distributed across Iran as part of Tekaje's portfolio of more than 150 molecules and dietary supplements. These products are sold through pharmacies and serve the broader consumer health market.
• Exerect Prescription pharmaceutical product in the urology therapeutic area, promoted at urology and neurology seminars. Distributed to pharmacies and hospitals across Iran as part of Tekaje's specialty pharmaceutical portfolio.
• Bicalox Pharmaceutical product in the urology therapeutic area, promoted alongside Exerect at urology seminars. Distributed through Tekaje's pharmacy and hospital network in Iran.
• Staparkin Neurology medication promoted at the Neurology & Clinical Electrophysiology Congress. Part of Tekaje's CNS/neurology pharmaceutical portfolio distributed to pharmacies and hospitals across Iran.
• Matever Anti-epilepsy medication promoted at neurology congresses including the Epilepsy Congress. Distributed through Tekaje's pharmacy network across Iran for the treatment of epilepsy patients.
• Hye Eye care pharmaceutical product promoted at ophthalmology congresses. Part of Tekaje's ophthalmology portfolio distributed to pharmacies across Iran.
• Xiloial Ophthalmic pharmaceutical product promoted at the Farabi Ophthalmology Congress. Distributed through Tekaje's pharmacy network for ophthalmology patients.
• Pure Eye care pharmaceutical product promoted at ophthalmology congresses. Part of Tekaje's ophthalmology portfolio distributed to pharmacies across Iran.
• EyeGel Ophthalmic gel formulation promoted at the Farabi Ophthalmology Congress. Distributed through Tekaje's pharmacy network for ophthalmology applications.

Quantifiable outcome

• 350 million units annual capacity
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• International PartnerscoreStrategic or Co-development PartnerTekaje has developed strong collaborations with international pharmaceutical partners to strengthen healthcare capabilities. Products are either acquired from partners, co-developed with them, or individually developed by R&D. The company integrates its established business structure, talented human resources, market knowledge, and infrastructure with partners who share common vision and complementary strengths.

Scale indicators9 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Julphar (Gulf Pharmaceutical Industries): UAE-headquartered generic and specialty pharmaceutical manufacturer with regional MENA distribution footprint. Closely comparable to Tekaje as a regional generic pharma manufacturer with vertically integrated formulation, manufacturing, and multi-country distribution.

Broad incumbents

• Cipla: India-headquartered global pharmaceutical company with one of the world's largest generic drug portfolios across dosage forms. Comparable to Tekaje as a generic-focused manufacturer with strong international partnerships and a broad molecule portfolio.
• Aspen Pharmacare: South Africa-based, JSE-listed global generic and specialty pharmaceutical manufacturer with operations across emerging markets. Comparable to Tekaje as an emerging-market generic pharma manufacturer with integrated manufacturing and broad distribution.
• Teva Pharmaceutical Industries: Israel-headquartered global leader in generic pharmaceuticals with operations across dosage forms. Comparable to Tekaje as a generic-pharma pure-play with manufacturing scale and broad distribution, though at materially larger scale.
• Aurobindo Pharma: India-headquartered global generic and API pharmaceutical manufacturer with vertically integrated operations. Comparable to Tekaje as a generics-focused dosage form manufacturer with a large molecule portfolio and active pipeline.
• Dr. Reddy's Laboratories: India-based, NYSE-listed global pharmaceutical company with significant generics, API, and specialty operations. Comparable to Tekaje as a vertically integrated generic drug manufacturer with global partnerships and active pipeline.
• Viatris: Global healthcare company formed from the Mylan/Upjohn combination, with a leading global generics and biosimilars portfolio. Comparable to Tekaje as a global generics manufacturer with broad therapeutic coverage and partnership-driven molecule sourcing.
• Hikma Pharmaceuticals: Jordan-headquartered, London-listed global generic and specialty pharmaceutical company with strong MENA presence. Comparable to Tekaje as a broadly diversified generic pharma company with a much larger portfolio and international reach.

Regional players

• EIPICO: One of the largest Egyptian pharmaceutical manufacturers, producing generics across multiple therapeutic areas for domestic and export markets. Comparable to Tekaje as a regional emerging-market generic pharma manufacturer with similar integrated model.
• SPIMACO: Saudi Arabia-listed pharmaceutical manufacturer producing branded generics across multiple therapeutic areas. Comparable to Tekaje as a GCC-region generics manufacturer with similar dosage-form portfolio and government-aligned regulatory positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/tkj

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tekaje